Stock Movers: JPM, WFC, UNH (Podcast)

JPMorgan’s third-quarter FICC sales and trading revenue missed estimates, marking its first such decline in more than two years, although CEO Jamie Dimon said each business line performed well. Wells Fargo’s third-quarter net interest income met the average analyst estimate. Johnson & Johnson raised profit guidance on demand for newer cancer and autoimmune drugs despite weaker medical-device growth, while UnitedHealth raised its full-year profit outlook after better-than-expected third-quarter earnings.

Analysis

The key distinction is between an earnings beat and evidence that earnings power is improving. For JPM, a FICC miss is a read-through to trading peers only if it reflects weaker client activity or market-making conditions rather than product-specific mix; watch the detailed desk breakdown and whether other businesses offset it. If isolated, the share reaction may overstate the signal. If broad-based, it challenges near-term trading assumptions across large banks. WFC merely meeting NII expectations offers little evidence of upside: deposit costs, loan growth and expense trends determine whether earnings estimates can move higher.

JNJ’s guidance improvement is a mix-shift positive, but the durability depends on launch trajectories and whether drug growth can outrun eventual product erosion; weak devices may constrain the consolidated growth narrative. UNH’s raised outlook is more vulnerable to a second-order reversal: higher utilization or medical-cost trends can absorb a profit beat quickly, while reimbursement and care-delivery execution remain important 6–18 month variables.

Over the next few days, price action may be driven more by the quality of guidance and calls than by the headline beats. Over 1–3 months, revisions to bank trading/NII and managed-care cost assumptions are the cleaner catalysts. There is no compelling basis here to chase any one-day move without the underlying segment data.

Key Decisions for Investors

• JPM: Keep exposure neutral pending the full release. Add on weakness only if FICC softness is demonstrably isolated and credit costs, NII and expense guidance remain sound; reduce if the miss is broad across desks or accompanied by weaker forward revenue commentary. Check rates, credit and equities trading separately.
• WFC: Do not treat an in-line NII result as an upgrade catalyst. Revisit only if deposit-cost trends and loan growth support upward NII revisions; a deteriorating deposit beta or weaker balances would falsify the stabilization case.
• UNH: Avoid chasing the initial reaction until medical-cost ratio/utilization detail and full-year guidance assumptions are clear. A rising cost trend or any rollback in the outlook would invalidate the positive read-through; sustained cost control would support the revision case.
• JNJ: Prefer a measured hold/add on pullbacks over buying a guidance headline. Monitor newer-drug growth, patent/lifecycle disclosures and device performance; slowing drug momentum or continued device weakness would undermine the mix-shift thesis.
• Across the group, use the earnings calls and subsequent estimate revisions—not the initial tape—as the 1–3 month decision point. No high-conviction pair trade is justified by the supplied information alone.